Seeking Alpha: Should Traders Try To Play The Odds With Cyclacel?

To be very clear from the get-go, I'm not bullish on the long-term prospects for Cyclacel ( CYCC ), nor those of its lead drug sapacit...

Investopedia: Pfizer Looking A Little Tired

At some point this bull market in all things health care will fade out, and I wonder if Pfizer (NYSE: PFE ) shares will maintain this sort ...

Investopedia: Celgene Only Getting Started, But The Street's Already Looking Ahead

Celgene (Nasdaq: CELG ) has been consistently profitable for a while, which is rare enough in the biotech space. What stands out to me wi...

Investopedia: Amgen Puts Onyx Pharmaceuticals In Play

Funny how an unsolicited bid will suddenly alert Wall Street to the value of a strong biotech. While Onyx Pharmaceuticals (Nasdaq: ONXX )...

Investopedia: Amgen Chased By The Bubble

There are two relatively heated debates that bear directly on Amgen (Nasdaq: AMGN ) and its stock. First, is Amgen still really a biotech,...